Clinical Trials

Stomach Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Phase 3 Recruiting

550 enrolled

Phase 2 Active not recruiting

Stomach Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

40 enrolled 67 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3 Recruiting

555 enrolled

Phase 2/3 Not yet recruiting

Stomach Neoplasms

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

490 enrolled

Phase 2 Active not recruiting

HER2-positive Gastric Cancer

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

217 enrolled 19 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT03615326 2025-12-11

MK-3475-811

Phase 3 Completed

738 enrolled 22 charts 7 FDA

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06328738 2025-11-19

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

275 enrolled

Phase 2/3 Active not recruiting

Colorectal Neoplasms

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

201 enrolled

Phase 2/3 Active not recruiting

Stomach Neoplasms

NCT05002127 2025-08-07

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

127 enrolled

Stomach Neoplasms

NCT04082364 2025-06-08

MAHOGANY

Phase 2/3 Completed

82 enrolled 22 charts

Phase 2 Not yet recruiting

Stomach Neoplasms

NCT06998771 2025-05-31

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

153 enrolled

Phase 2 Not yet recruiting

HER2-positive Gastric Cancer

NCT06589830 2025-05-15

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

80 enrolled

Neoplasms, Colorectal Neoplasms

NCT01649271 2025-02-11

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

13 enrolled 11 charts

Breast Neoplasms, Stomach Neoplasms

NCT04499924 2025-01-22

MOUNTAINEER-02

Phase 2/3 Completed

17 enrolled 23 charts

Adenocarcinoma Of Esophagus

NCT05555251 2024-12-16

CONTRAST

18 enrolled

HER2-positive Breast Cancer

NCT05207722 2024-12-12

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

1 enrolled

Stomach Neoplasms

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

117 enrolled 21 charts 2 FDA

Colorectal Neoplasms

NCT04281576 2024-11-14

Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Phase NA Completed

28 enrolled

Stomach Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

GastrointestinalGenitourinary

673 enrolled 22 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT02291289 2024-05-06

MODUL

1,044 enrolled 21 charts

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT04908813 2024-04-15

Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

150 enrolled

Phase EARLY_PHASE1 Unknown

Stomach Neoplasms

NCT06098898 2023-10-25

Safety and Efficacy of NK510 to Treat Gastric Cancer

9 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Stomach Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05765357 2023-03-13

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

89 enrolled

Breast Neoplasms, Stomach Neoplasms

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

201 enrolled 71 charts

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

BreastGastrointestinalThoracic

2 enrolled 9 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT03319459 2021-11-22

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

44 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Phase 1/2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01774786 2020-12-30

JACOB

Phase 3 Completed

780 enrolled 24 charts

Stomach Neoplasms

NCT01602406 2020-12-19

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

64 enrolled

Stomach Neoplasms

NCT01402401 2020-12-10

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Phase 2 Terminated

21 enrolled

Stomach Neoplasms

NCT03680560 2020-03-31

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Phase 1 Terminated

6 enrolled

Breast Neoplasms, Carcinoma, Adenoid Cystic, Stomach Neoplasms

NCT01748773 2019-10-09

TOXAG

34 enrolled

Stomach Neoplasms

NCT01461057 2018-08-09

JOSHUA

30 enrolled 9 charts

Stomach Neoplasms

NCT01839500 2018-03-29

EVIDENCE

Completed

1,600 enrolled

Stomach Neoplasms

NCT01774851 2017-06-22

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Phase 2 Terminated

84 enrolled 10 charts

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT01450696 2016-11-28

HELOISE

Phase 3 Terminated

296 enrolled 16 charts

Stomach Neoplasms

NCT01260194 2016-11-02

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

Phase 4 Terminated

4 enrolled 11 charts

Stomach Neoplasms

NCT02731313 2016-10-28

Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma

Completed

420 enrolled 8 charts

Stomach Neoplasms

NCT01384253 2016-09-30

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy